Cefuroxime — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO (cefuroxime axetil)	10-20 mg/kg	q12h	Duration: 5-7 days or as clinically indicated Notes: Administer with food to enhance absorption.
Dog	IV or IM (cefuroxime sodium)	10-25 mg/kg	q8h	Duration: 5-7 days or as clinically indicated Notes: For severe infections, higher doses may be used.
Cat	PO (cefuroxime axetil)	10-20 mg/kg	q12h	Duration: 5-7 days or as clinically indicated Notes: Administer with food.
Cat	IV or IM (cefuroxime sodium)	10-25 mg/kg	q8h	Duration: 5-7 days or as clinically indicated Notes: For severe infections, higher doses may be used.
Horse	IV or IM	10-20 mg/kg	q8h	Duration: 5-7 days or as clinically indicated Notes: Oral administration is not recommended due to poor bioavailability.
Cattle	IV or IM	10-20 mg/kg	q12h	Duration: 3-5 days Notes: Extra-label use; observe withdrawal times.
Small Ruminants (sheep, goats)	IV or IM	10-20 mg/kg	q12h	Duration: 3-5 days Notes: Extra-label use; observe withdrawal times.
Rabbit	PO (cefuroxime axetil)	10-20 mg/kg	q12h	Duration: 5-7 days Notes: Limited data; use with caution.
Rabbit	IV or IM	10-25 mg/kg	q8h	Duration: 5-7 days Notes: Limited data; use with caution.

Clinical Indications & Species Uses

General Indications

Treatment of infections caused by susceptible Gram-positive and Gram-negative bacteria, including beta-lactamase-producing strains.

Dog (Canine)

Treatment of bacterial infections caused by susceptible organisms, including skin and soft tissue infections, urinary tract infections, respiratory tract infections, and septicemia.

Cat (Feline)

Treatment of bacterial infections caused by susceptible organisms, including skin and soft tissue infections, urinary tract infections, respiratory tract infections, and septicemia.

Cattle (Bovine)

Treatment of respiratory disease (e.g., bovine respiratory disease complex) and other susceptible bacterial infections; extra-label use is common.

Small Ruminants (Sheep / Goat)

Treatment of bacterial infections caused by susceptible organisms; extra-label use.

Rabbit & Small Mammals

Treatment of bacterial infections caused by susceptible organisms; extra-label use.

Pharmacology & Mechanism of Action

Drug Class: Cephalosporin antibiotic | Pharmacological Group: Second-generation cephalosporin

Mechanism of Action: Cefuroxime is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) located on the bacterial cell membrane. This binding disrupts the cross-linking of peptidoglycan chains, leading to a weakened cell wall and eventual cell lysis. Cefuroxime is generally bactericidal and has a broad spectrum of activity against both Gram-positive and Gram-negative bacteria, including many beta-lactamase-producing strains due to its stability against certain beta-lactamases.

Pharmacodynamics: Cefuroxime exhibits time-dependent killing, meaning its efficacy is related to the duration of time that the drug concentration remains above the minimum inhibitory concentration (MIC) for the pathogen. It is stable to many plasmid-mediated beta-lactamases, but can be hydrolyzed by extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases. Its spectrum includes Staphylococcus spp. (including penicillinase-producing strains), Streptococcus spp., Escherichia coli, Klebsiella spp., Proteus mirabilis, and some anaerobes. It has limited activity against Pseudomonas aeruginosa, Enterococcus spp., and methicillin-resistant staphylococci.

⚡ Pharmacokinetics Summary

Absorption: Cefuroxime is poorly absorbed orally; the oral prodrug cefuroxime axetil is used to improve absorption. In dogs and cats, oral bioavailability of cefuroxime axetil is approximately 50-60% when given with food. In horses, oral absorption is erratic and not recommended. Parenteral administration (IV, IM) results in complete bioavailability.

Distribution: Cefuroxime is widely distributed into body tissues and fluids, including pleural, peritoneal, and synovial fluids. It crosses the blood-brain barrier only when the meninges are inflamed. It crosses the placenta and is distributed into milk. Volume of distribution is approximately 0.2-0.3 L/kg in dogs.

Metabolism: Cefuroxime is minimally metabolized in the liver; the majority of the drug is excreted unchanged by the kidneys. It is not significantly metabolized in most species.

Excretion: Cefuroxime is primarily eliminated by renal excretion via glomerular filtration and tubular secretion. In animals with normal renal function, the elimination half-life is short (approximately 1-2 hours in dogs and cats). In renal impairment, the half-life is prolonged and dose adjustment may be necessary.

Half-Life: Dogs: 1-2 hours; Cats: 1-2 hours; Horses: 1.5-2 hours; Cattle: 1-2 hours; Rabbits: 1-2 hours (estimated)

Bioavailability: Oral (cefuroxime axetil): ~50-60% in dogs and cats when administered with food; IM: ~100%

Protein Binding: Cefuroxime is approximately 33-50% bound to plasma proteins in humans; in dogs, protein binding is about 20-30%.

Available Formulations & Strengths

Oral Tablet (cefuroxime axetil) 125 mg, 250 mg, 500 mg (PO)

Oral Suspension (cefuroxime axetil) 125 mg/5 mL, 250 mg/5 mL (PO)

Injectable Solution (cefuroxime sodium) 750 mg, 1.5 g, 7.5 g (as powder for reconstitution) (IV, IM)

Contraindications & Clinical Warnings

Contraindications:

Known hypersensitivity to cefuroxime or other cephalosporins
History of severe allergic reactions to penicillins (cross-sensitivity may occur)
Do not use in animals with a history of anaphylactic reactions to beta-lactam antibiotics

Warnings & Clinical Precautions:

Use with caution in animals with renal impairment; dose adjustment may be necessary.
Use with caution in animals with a history of gastrointestinal disease, especially colitis.
Prolonged use may result in overgrowth of non-susceptible organisms, including Clostridioides difficile.
In food-producing animals, observe withdrawal times to avoid drug residues.
Cefuroxime axetil tablets should be swallowed whole; do not crush or chew.
Administer oral cefuroxime with food to enhance absorption and reduce GI upset.

Adverse Effects & Reactions

Common:

Gastrointestinal disturbances (vomiting, diarrhea, anorexia)
Injection site pain or inflammation (with IM administration)
Hypersensitivity reactions (skin rash, urticaria)

Serious / Severe:

Anaphylaxis
Clostridioides difficile-associated diarrhea
Renal toxicity (rare)
Hematologic abnormalities (neutropenia, thrombocytopenia)

Rare:

Seizures (especially with high doses in renal impairment)
Hepatotoxicity
Superinfection with resistant organisms

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Probenecid	Probenecid decreases renal tubular secretion of cefuroxime, increasing its plasma concentration and half-life.	Moderate
Aminoglycosides (e.g., gentamicin)	Additive nephrotoxicity; monitor renal function when used concurrently.	High
Loop diuretics (e.g., furosemide)	May increase the risk of nephrotoxicity.	Moderate
Bacteriostatic antibiotics (e.g., tetracyclines, chloramphenicol)	May antagonize the bactericidal effect of cefuroxime; avoid concurrent use.	Moderate
Warfarin	Cephalosporins may enhance the anticoagulant effect; monitor coagulation parameters.	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Gastrointestinal signs (vomiting, diarrhea)
Neurological signs (seizures, tremors) in severe cases
Renal toxicity (increased BUN/creatinine)

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive. Induce emesis if recent oral ingestion and the animal is conscious. Administer activated charcoal to reduce absorption. Provide fluid therapy to maintain renal perfusion and enhance elimination. Monitor renal function and neurological status. In severe cases, hemodialysis may be considered.

Food Animal Withdrawal Times

🥩 Meat: 5 days🥛 Milk: 3 days

Withdrawal times are not established for cefuroxime in food animals; these are suggested based on similar cephalosporins. Consult regulatory guidelines and use extra-label with caution.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light. Keep in a dry place. Reconstituted injectable solutions are stable for 24 hours at room temperature or 48 hours under refrigeration.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Cefuroxime is not FDA-approved for veterinary use in the US; it is used extra-label. Approved for human use.

Extra-Label (Off-Label) Use: In the US, extra-label use of cephalosporins in food animals is prohibited (or restricted) by the FDA. Specifically, the use of cephalosporins (including cefuroxime) in cattle, swine, chickens, and turkeys is prohibited for disease prevention; extra-label use is only allowed for therapeutic purposes under specific conditions and with veterinary oversight. Check current regulations.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Cefuroxime is a second-generation cephalosporin with good activity against many common veterinary pathogens, including Staphylococcus spp., Streptococcus spp., E. coli, and Klebsiella spp. It is often used as a first-line antibiotic for skin, respiratory, and urinary tract infections in dogs and cats. However, its use is limited by the need for frequent dosing (q8h) and the availability of other cephalosporins with longer half-lives (e.g., cefpodoxime, cefovecin). In horses, cefuroxime is used for respiratory infections but is not the preferred choice due to cost and availability. In food animals, extra-label use is restricted, and other cephalosporins may be more practical. Always perform culture and sensitivity testing when possible, and use the lowest effective dose for the shortest duration to minimize resistance development. Monitor renal function in animals with pre-existing renal disease or when using nephrotoxic drugs concurrently.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)